Immunic, Inc. Bolsters Board of Directors with Appointment of Industry Veteran Jon Congleton

Key Points for Investors

• Immunic, Inc. (Nasdaq: IMUX) appoints Jon Congleton, a seasoned biopharmaceutical executive with nearly 40 years’ experience, to its Board of Directors effective March 27, 2026.
• Congleton’s experience includes leadership in the launch of Copaxone®—the top prescribed treatment for multiple sclerosis (MS) in the United States.
• He is currently CEO and board member of Mineralys Therapeutics, Inc., and has held C-suite and board positions at Impel NeuroPharma, Nivalis Therapeutics, and senior leadership roles at Teva Pharmaceuticals.
• His appointment comes as Immunic advances its lead drug candidate, vidofludimus calcium (IMU-838), through pivotal phase 3 clinical trials for relapsing MS, with top-line data expected by the end of 2026.
• Vidofludimus calcium is positioned as a potentially transformative oral therapy for MS, with neuroprotective, anti-inflammatory, and anti-viral properties, and a favorable safety and tolerability profile.
• This strategic board addition aligns with Immunic’s transition toward becoming a fully integrated, commercial-stage biotech company.

Details and Insights for Shareholders

Immunic, Inc., a late-stage biotechnology company focused on developing novel oral therapies for neurologic diseases, has strengthened its Board of Directors with the high-profile appointment of Jon Congleton. His nearly four decades in the biopharmaceutical industry includes extensive experience in drug development, commercialization, and leadership, particularly in the central nervous system (CNS) arena and multiple sclerosis.

Congleton’s career highlights include his pivotal role in the U.S. launch and subsequent commercial leadership of Teva Pharmaceuticals’ Copaxone®, a market-leading subcutaneous MS treatment. Under his leadership, Copaxone® became the number one prescribed MS therapy nationwide. His commercial expertise, especially in taking innovative therapies from late-stage development through to regulatory approval and market leadership, is expected to be a significant asset for Immunic as it advances its own MS program.

Currently, Congleton is CEO and board member at Mineralys Therapeutics, where he led the company from an early-stage private entity to a publicly traded, pre-commercial biotech focused on cardiorenal conditions. His previous C-suite and board experience at CNS and cystic fibrosis companies, as well as his tenure at Teva overseeing U.S. and Canadian neuroscience operations, further solidify his track record in creating long-term value and guiding firms through critical corporate milestones.

Shareholder-Relevant Highlights:

• Strategic Timing: Congleton’s appointment comes as Immunic is on the cusp of major clinical milestones, specifically the anticipated pivotal trial readouts for vidofludimus calcium by the end of 2026—a potentially price-sensitive event that could significantly impact share value depending on trial outcomes.
• Transition to Commercial Stage: The company is proactively evolving its board to support its shift from pure clinical development to a fully integrated commercial-stage organization, which is often associated with re-rating opportunities in the biotech sector.
• Pipeline Potential: Vidofludimus calcium (IMU-838) is currently in phase 3 trials for relapsing MS and has already shown efficacy in phase 2 trials for multiple sclerosis and other diseases. This first-in-class Nurr1 activator could offer competitive advantages due to its combined neuroprotective, anti-inflammatory, and anti-viral effects, alongside a favorable safety and tolerability profile.
• Pipeline Expansion: Immunic’s pipeline also includes earlier-stage assets (IMU-856, IMU-381) targeting neurodegenerative, chronic inflammatory, and autoimmune-related diseases, further broadening the company’s potential commercial footprint.

In statements, both Immunic’s Interim Chairperson, Simona Skerjanec, and Jon Congleton highlighted the significance of this board evolution and the transformative potential of vidofludimus calcium for MS patients. Congleton specifically referenced the opportunity to offer advantages over currently available therapies and expressed enthusiasm for contributing his expertise as the company approaches key clinical readouts later this year.

Forward-Looking Statements and Risks

Immunic cautions investors that this press release contains forward-looking statements regarding future operations, development timelines, regulatory milestones, and commercial prospects, which involve substantial risks and uncertainties. These include, but are not limited to, the outcomes of ongoing and future clinical trials, the ability to secure sufficient capital, potential impacts of macroeconomic trends and global conflicts, and regulatory hurdles. Investors are urged not to place undue reliance on forward-looking statements, as actual results may differ materially.

Investor Contacts

• Jessica Breu, VP Investor Relations and Communications, Immunic, Inc.: +49 89 2080 477 09, [email protected]
• Paula Schwartz, Rx Communications Group (US IR): +1 917 633 7790, [email protected]
• Caitlin Kasunich, KCSA Strategic Communications (US Media): +1 212 896 1241, [email protected]

Disclaimer

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with financial advisors before making any investment decision. The information herein reflects publicly available data and company statements as of the date of publication and is subject to change without notice.

View IMMUNIC, INC. Historical chart here